Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

types, of which HPV-16 is the most common. In the U.S., these infections are typically discovered through nearly 60 million Pap screens completed each year, at a cost of up to $6 billion. Each year in the U.S., an estimated 1.2 million women are diagnosed with low grade cervical dysplasia (CIN 1), 300,000 with high grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the FDA for the treatment of any type of CIN.

About HspE7:

The company's lead product candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by HPV. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include statements rega
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Peptide Cancer Therapeutics Market & Pipeline Insight 2014" ... methods developed to prevent and eradicate the prevalence of ... methods are confined to low specificity, safety and large ... look for a better solution. It has been discovered ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... report, "Amaranth Seed Oil Market by Extraction type (SFE, ... (Cosmetic & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & ... published by MarketsandMarkets, defines and segments the Amaranth ... of the market size in terms of value. ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pharmaceutical Equipment Market in China, 2014-2018" report to ... Forecast of Pharmaceutical Equipment Market in China ... pharmaceutical equipment industry in the aspects of current ... performance of domestic major enterprises, as well as offers ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... issue of the Journal of Neuroscience a ... and National Jewish,Medical and Research Center demonstrating ... AEOL 11207, demonstrated,neuroprotection in an animal model ...
... adding Diovan to conventional therapy , , , Study ... , , BASEL,Switzerland, April 27, 2007 ... published today in The Lancet[1], show that,adding the blood ... 39% reduction in,cardiovascular events and a 40% reduction in ...
Cached Medicine Technology:Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
(Date:8/29/2014)... The Fibroids Miracle review indicates that this is a new ... and powerful results. It actually claims to be able to ... 12 hours. The method promises to lead to a permanent ... on a 3 step method that has never been revealed ... was in fact created by someone who had an important ...
(Date:8/29/2014)... Daily Gossip reveals in its Stop Sciatica ... method of naturally curing this disease. , The program ... permanent cure in only one week. This is described as ... make huge sacrifices. , Moreover, with this new method ... of sciatica in just 8 minutes. , Interested customers ...
(Date:8/29/2014)... Skmen.com, a famous online supplier of trendy clothes, has unveiled ... the moment, all these mini outfits are offered at discounted ... promotion is September 14. , The company’s senior spokesman ... our hot designs, we have listed some of the best-selling ... stylish ladies to get high quality, fashionable clothes. Many of ...
(Date:8/29/2014)... Indosoft, Inc., a leading provider of scalable Asterisk-based ... licensing of its Q-Suite 5.7 software. As a ... been successfully deploying and supporting its ACD and Dialer ... the world for more than a decade. The introduction ... option which complements the widespread deployment of Q-Suite in ...
(Date:8/29/2014)... 2014 Developed as a nod to ... Canada Goose products offer the mobility, durability ... Arctic runways. The company’s Canada Goose Chilliwack bombers ... current market. Additionally, the firm has unveiled its new ... , At present, all high quality Chilliwack bombers are ...
Breaking Medicine News(10 mins):Health News:Fibroids Miracle Review Exposes Amanda Leto’s 3-Step Holistic System 2Health News:Stop Sciatica in 8 Minutes Review Exposes Steven Guo's Complete Sciatica Cure 2Health News:Cheap Sexy Mini Dresses Added To The Product Line Of Skmen.com 2Health News:Indosoft Offers Monthly Usage Licensing Terms 2Health News:New Designs Of Canada Goose Chilliwack Bombers From DoudouneCanadienneGoosePasCher.fr 2
... metabolism in weeks , , MONDAY, April 7 (HealthDay News) ... a person at an increased risk for heart disease ... team of French researchers studying the drug,s effect on ... weeks, the rodents, blood sugar levels rose significantly ...
... the use of robotics for minimally invasive cardiac surgery. ... cardiac surgery. With his arrival, BMC has become one ... the only hospital in Boston, to offer robot-assisted minimally invasive ... artery disease (the most common form of heart disease - ...
... LEANDRO, Calif., April 7, 2008 A,tiny lightstick -- ... of,all fatalities from oral cancer, according to the East ... dental group which,recommends that all adults ask their dentists ... procedure with this product will become,as widespread as the ...
... Nutrition 21,Inc. (Nasdaq: NXXI ), a developer ... sugar levels, improve cardiovascular,health, enhance memory and address chronic ... elected to the Company,s Board of Directors,effective April 7, ... Executive Officer of Iceland,Health, Inc. a company acquired by ...
... matter of molecular To Tell the Truth, as scientists ... from those that are imposters. Powerful gene-scanning technology often ... tissue, making it critical for investigators to winnow out ... the April 8 issue of the journal Cancer Cell, ...
... WOODBURY, N.Y., April 7, 2008 CardWorks Servicing, ... servicer,formerly known as Cardholder Management Services, LLC ("CMS"), ... service the new HumanaAdvance,Visa Card. CardWorks will partner ... to offer the HumanaAdvance Visa. Humana,is one of ...
Cached Medicine News:Health News:Antipsychotic Drug Boosts Risk of Heart Disease, Diabetes 2Health News:Robot-assisted minimally-invasive CABG surgery 2Health News:New ViziLite Plus Could Reduce Oral Cancer Fatalities Predicts East Bay's Creative Dimensions in Dentistry 2Health News:Nutrition 21 Elects Mark H. Stenberg to Board of Directors 2Health News:Data-handling technique finds genes to be team players in curbing brain cancer cell growth 2Health News:Data-handling technique finds genes to be team players in curbing brain cancer cell growth 3Health News:CardWorks Named Servicer of Choice for Innovative Credit Card for Healthcare Services 2Health News:CardWorks Named Servicer of Choice for Innovative Credit Card for Healthcare Services 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
The HT-PB is a implantable bipolar tined permanent pacing lead for stimulation of the ventricle....
Medicine Products: